Verastem Beheer

Beheer criteriumcontroles 1/4

Verastem's CEO is Dan Paterson, appointed in Jun 2019, has a tenure of 5.42 years. total yearly compensation is $3.63M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.098% of the company’s shares, worth $154.66K. The average tenure of the management team and the board of directors is 1.6 years and 3.2 years respectively.

Belangrijke informatie

Dan Paterson

Algemeen directeur

US$3.6m

Totale compensatie

Percentage CEO-salaris	15.0%
Dienstverband CEO	5.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dan Paterson's beloning veranderd ten opzichte van Verastem's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$4m	US$545k	-US$87m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$698k	US$470k	-US$74m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$2m	US$460k	-US$71m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$2m	US$467k	-US$68m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$445k	-US$149m

Compensatie versus markt: Dan's total compensation ($USD3.63M) is above average for companies of similar size in the US market ($USD1.48M).

Compensatie versus inkomsten: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Paterson (63 yo)

5.4yrs

Tenure

US$3,626,857

Compensatie

Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Paterson	President	5.4yrs	US$3.63m	0.098% $ 154.7k
Daniel Calkins	CFO and Principal Accounting & Financial Officer	2.1yrs	US$622.56k	0.017% $ 26.5k
Richard Aldrich	Founder and Consultant	10.2yrs	US$114.77k	geen gegevens
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Piyush Gupta	Co-Founder	no data	geen gegevens	geen gegevens
Michelle Dipp	Co-Founder	no data	geen gegevens	geen gegevens
Jonathan Pachter	Chief Scientific Officer	8.6yrs	US$319.51k	geen gegevens
Cathy Carew	Chief Organizational Effectiveness Officer	no data	geen gegevens	geen gegevens
Nate Sanburn	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Michael Crowther	Chief Commercial & Strategy Officer	1.1yrs	geen gegevens	geen gegevens
Colleen Mockbee	Global Head of Regulatory Affairs & Development	less than a year	geen gegevens	geen gegevens
John Hayslip	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: VSTM's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Paterson	President	1.3yrs	US$3.63m	0.098% $ 154.7k
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mario Sznol	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Kauffman	Lead Independent Director	12yrs	US$124.29k	0.0014% $ 2.2k
Paul A. Bunn	Independent Director	3.4yrs	US$74.29k	0% $ 0
Eric Rowinsky	Independent Director	7.5yrs	US$89.29k	0% $ 0
John Johnson	Independent Director	4.6yrs	US$81.29k	0% $ 0
Robert Gagnon	Director	1.9yrs	US$64.29k	0.062% $ 98.5k
Channing Der	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Brian Stuglik	Director	7.2yrs	US$2.30m	0.24% $ 376.8k
Anil Kapur	Independent Director	2.1yrs	US$81.75k	0% $ 0
Michelle Robertson	Independent Director	3yrs	US$84.29k	0% $ 0

3.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: VSTM's board of directors are considered experienced (3.2 years average tenure).

Verastem Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Announces Executive Appointments

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Recent updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur